Docosahexaenoic acid and its role in G-protein-coupled receptor 120 activation in children affected by nonalcoholic fatty liver disease

Endocrine Development

Volumn 30, Issue , 2016, Pages 29-36

  Corte, Claudia Della ^a   Mosca, Antonella ^a   Ionata, Aurelio ^b   Nobili, Valerio ^a  

^a BAMBINO GESÙ CHILDREN S HOSPITAL   (Italy)

^b Azienda Sanitaria Regionale Del Molise (ASReM)   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

DOCOSAHEXAENOIC ACID; G PROTEIN COUPLED RECEPTOR 120; HIGH DENSITY LIPOPROTEIN; LOW DENSITY LIPOPROTEIN; TRIACYLGLYCEROL; ANTIDIABETIC AGENT; ANTIINFLAMMATORY AGENT; G PROTEIN COUPLED RECEPTOR; O3FAR1 PROTEIN, HUMAN;

ANTIINFLAMMATORY ACTIVITY; ARTICLE; CHILD; ENZYME ACTIVATION; HUMAN; KUPFFER CELL; LIVER INJURY; LIVER METABOLISM; NONALCOHOLIC FATTY LIVER; PEDIATRICS; PRIORITY JOURNAL; SUPPLEMENTATION; DRUG EFFECTS; NON-ALCOHOLIC FATTY LIVER DISEASE;

ANTI-INFLAMMATORY AGENTS; CHILD; DOCOSAHEXAENOIC ACIDS; HUMANS; HYPOGLYCEMIC AGENTS; NON-ALCOHOLIC FATTY LIVER DISEASE; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84951200693     PISSN: 14217082     EISSN: 16622979     Source Type: Book Series    
DOI: 10.1159/000439324     Document Type: Article

References (27)

1. Burri L, Hoem N, Banni S, Berge K: Marine omega-3 phospholipids: metabolism and biological activities. Int J Mol Sci 2012; 13: 15401-15419.
2. Simopoulos AP: The importance of the ratio of omega-6/omega-3 essential fatty acids. Biomed Pharmacother 2002; 56: 365-379.
3. Kwak SM, Myung SK, Lee YJ, Seo HG: Efficacy of omega-3 fatty acid supplements (eicosapentaenoic acid and docosahexaenoic acid) in the secondary prevention of cardiovascular disease: a meta-analysis of randomized, double-blind, placebo-controlled trials. Arch Intern Med 2012; 172: 686-694.
4. Calder PC: Omega-3 polyunsaturated fatty acids and inflammatory processes: nutrition or pharmacology? Br J Clin Pharmacol 2013; 75: 645-662.
5. Pinel A, Morio-Liondore B, Capel F: n-3 polyunsaturated fatty acids modulate metabolism of insulinsensitive tissues: implication for the prevention of type 2 diabetes. J Physiol Biochem 2014; 70: 647-658.
6. Oh DY, Talukdar S, Bae EJ, Imamura T, Morinaga H, Fan W, Li P, Lu WJ, Watkins SM, Olefsky JM: GPR120 is an omega-3 fatty acid receptor mediating potent anti-inflammatory and insulin-sensitizing effects. Cell 2010; 142: 687-698.
7. Parker HM, Johnson NA, Burdon CA, Cohn JS, O'Connor HT, George J: Omega-3 supplementation and non-alcoholic fatty liver disease: a systematic review and meta-analysis. J Hepatol 2012; 56: 944-951.
8. Brunt EM: Nonalcoholic fatty liver disease: what the pathologist can tell the clinician. Dig Dis 2012; 30(suppl 1):61-68.
9. Alisi A, Manco M, Vania A, Nobili V: Pediatric nonalcoholic fatty liver disease in 2009. J Pediatr 2009; 155: 469-474.
10. Vernon G, Baranova A, Younossi ZM: Systematic review: the epidemiology and natural history of nonalcoholic fatty liver disease and non-alcoholic steatohepatitis in adults. Aliment Pharmacol Ther 2011; 34: 274-285.
11. Stillwell W, Wassall SR: Docosahexaenoic acid: membrane properties of a unique fatty acid. Chem Phys Lipids 2003; 126: 1-27.
12. Jump DB, Botolin D, Wang Y, Xu J, Demeure O, Christian B: Docosahexaenoic acid (DHA) and hepatic gene transcription. Chem Phys Lipids 2008; 153: 3-13.
13. Raptis DA, Limani P, Jang JH, Ungethum U, Tschuor C, Graf R, Humar B, Clavien PA: GPR120 on Kupffer cells mediates hepatoprotective effects of 3-fatty acids. J Hepatol 2014; 60: 625-632.
14. Feldstein AE, Charatcharoenwitthaya P, Treeprasertsuk S, Benson JT, Enders FB, Angulo P: The natural history of nonalcoholic fatty liver disease in children: a follow-up study for up to 20 years. Gut 2009; 58: 1538-1544.
15. Schwimmer JB, Deutsch R, Kahen T, Lavine JE, Stanley C, Behling C: Prevalence of fatty liver in children and adolescents. Pediatrics 2006; 118: 1388-1393.
16. Alisi A, Cianfarani S, Manco M, Agostoni C, Nobili V: Non-alcoholic fatty liver disease and metabolic syndrome in adolescents: pathogenetic role of genetic background and intrauterine environment. Ann Med 2012; 44: 29-40.
17. Nobili V, Donati B, Panera N, Vongsakulyanon A, Alisi A, Dallapiccola B, Valenti L: A four-polymorphism risk score predicts steatohepatitis in children with non-alcoholic fatty liver disease. J Pediatr Gastroenterol Nutr 2014; 58: 632-636.
18. Samuel VT, Liu ZX, Qu X, Elder BD, Bilz S, Befroy D, Romanelli AJ, Shulman GI: Mechanism of hepatic insulin resistance in non-alcoholic fatty liver disease. J Biol Chem 2004; 279: 32345-32353.
19. Nobili V, Svegliati-Baroni G, Alisi A, Miele L, Valenti L, Vajro P: A 360-degree overview of paediatric NAFLD: recent insights. J Hepatol 2013; 58: 1218-1229.
20. Della Corte C, Liccardo D, Ferrari F, Alisi A, Nobili V: Current pharmacotherapy for treating pediatric nonalcoholic fatty liver disease. Expert Opin Pharmacother 2014; 15: 2501-2511.
21. Nobili V, Bedogni G, Alisi A, Pietrobattista A, Rise P, Galli C, Agostoni C: Docosahexaenoic acid supplementation decreases liver fat content in children with non-alcoholic fatty liver disease: double blind randomized controlled clinical trial. Arch Child 2011; 96: 350-353.
22. Nobili V, Alisi A, Della Corte C, Rise P, Galli C, Agostoni C, Bedogni G: Docosahexaenoic acid for the treatment of fatty liver: randomized controlled trial in children. Nutr Metab Cardiovasc Dis 2013; 23: 1066-1070.
23. Jaczyk W, Socha P, Lebensztejn D, Wierzbicka A, Mazur A, Neuhoff-Murawska J, Matusik P: Omega-3 fatty acid for treatment of non-alcoholic fatty liver disease: design and rationale of randomized controlled trial. BMC Pediatr 2013; 23: 13-85.
24. Nobili V, Carpino G, Alisi A, De Vito R, Franchitto A, Alpini G, Onori P, Gaudio E: Role of docosahexaenoic acid treatment in improving liver histology in pediatric nonalcoholic fatty liver disease. PLoS One 2014; 9:e88005.
25. Nobili V, Bedogni G, Donati B, Alisi A, Valenti L: The I148M variant of PNPLA3 reduces the response to docosahexaenoic acid in children with non-alcoholic fatty liver disease. J Med Food 2013; 16: 957-960.
26. Marzuillo P, Grandone A, Conte M, Capuano F, Cirillo G, Di Sessa A, Umano GR, Romano R, Perrone L, del Giudice EM: Novel association between a nonsynonymous variant (R207H) of the G-proteincoupled receptor 120 and liver injury in children and adolescents with obesity. J Pediatr Gastroenterol Nutr 2014; 59: 472-475.
27. Nobili V, Alkhouri N, Alisi A, Della Corte C, Fitzpatrick E, Raponi M, Dhawan A: Nonalcoholic fatty liver disease: a challenge for pediatricians. JAMA Pediatr 2015; 169: 170-176.